Stockscreener 앱 받기
29.86
1.05%
0.31
시장 영업 전:
29.91
0.05
+0.17%
전일 마감가:
$29.55
열려 있는:
$29.9
하루 거래량:
2.08M
Relative Volume:
0.72
시가총액:
$4.60B
수익:
$264.79M
순이익/손실:
$-14.36M
주가수익비율:
-271.45
EPS:
-0.11
순현금흐름:
$-28.11M
1주 성능:
+0.40%
1개월 성능:
-7.27%
6개월 성능:
+42.19%
1년 성능:
+98.14%
1일 변동 폭
$29.51
$30.33
1주일 범위
$28.62
$31.02
52주 변동 폭
$12.84
$36.84
TG테라퓨틱스사 Stock (TGTX) Company Profile
명칭
Tg Therapeutics Inc
전화
(212) 554-4484
주소
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
TGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
29.86 | 4.60B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
TG테라퓨틱스사 Stock (TGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-29 | 개시 | TD Cowen | Buy |
| 2023-08-02 | 업그레이드 | Goldman | Sell → Neutral |
| 2023-06-26 | 재개 | Jefferies | Buy |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-01 | 개시 | JP Morgan | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 개시 | Evercore ISI | Outperform |
| 2020-01-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2018-09-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 재개 | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 재개 | H.C. Wainwright | Buy |
| 2017-04-25 | 개시 | Jefferies | Buy |
| 2017-03-06 | 재확인 | FBR & Co. | Outperform |
| 2016-10-06 | 재개 | Brean Capital | Buy |
| 2016-05-27 | 개시 | SunTrust | Buy |
| 2015-12-01 | 개시 | FBR Capital | Outperform |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-08-12 | 재개 | H.C. Wainwright | Buy |
| 2015-06-19 | 재확인 | Brean Capital | Buy |
| 2014-12-11 | 재확인 | ROTH Capital | Buy |
| 2014-12-10 | 재확인 | ROTH Capital | Buy |
모두보기
TG테라퓨틱스사 주식(TGTX)의 최신 뉴스
Analysts Issue Forecasts for TG Therapeutics FY2025 Earnings - MarketBeat
Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha
12 Hot Stocks to Buy According to Analysts - Insider Monkey
Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN
(TGTX) Trading Signals - Stock Traders Daily
Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN
TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
Have Insiders Sold TG Therapeutics Shares Recently? - Simply Wall St
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts - Benzinga
10 Firms Post Impressive Gains on Tuesday - Insider Monkey
Why TGTX Stock Is Rallying Today - MSN
TG Therapeutics Reports Strong Revenue and Future Goals - TipRanks
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug - MarketWatch
TG Therapeutics Provides Preliminary Fourth Quarter and - GlobeNewswire
TG Therapeutics (NASDAQ:TGTX) Shares Gap UpHere's Why - MarketBeat
TG Therapeutics projects $540 million in 2025 revenue By Investing.com - Investing.com Nigeria
What's Going On With TG Therapeutics Stock Tuesday? - Benzinga
TG Therapeutics says 2024 Briumvi sales topped expectations - MSN
TG Therapeutics stock rises on strong Q4 and full-year revenue - Investing.com Nigeria
TG Therapeutics stock rises on strong Q4 and full-year revenue By Investing.com - Investing.com South Africa
TG Therapeutics stock gains on Briumvi sales (TGTX:NASDAQ) - Seeking Alpha
TG Therapeutics projects $540 million in 2025 revenue - Investing.com
TG Therapeutics' BRIUMVI Hits $310M Revenue in 2024, Projects 75% Growth for 2025 - StockTitan
Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $40.67 - MarketBeat
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst (NASDAQ:TGTX) - Seeking Alpha
JPMorgan Chase & Co. Buys 270,286 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Should You Invest in TG Therapeutics (TGTX)? - Insider Monkey
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
TG Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Vanguard Group Inc's Strategic Acquisition of TG Therapeutics In - GuruFocus.com
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
TG Therapeutics CFO Sean Power sells $629,382 in common stock - Investing.com India
TG Therapeutics price target raised to $10 from $9 at BofA - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Rating Increased to Hold at StockNews.com - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power Sells 10,021 Shares - MarketBeat
Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells 11,337 Shares of Stock - MarketBeat
TG Therapeutics CFO Sean Power sells $629,382 in common stock By Investing.com - Investing.com Nigeria
How To Trade (TGTX) - Stock Traders Daily
TG Therapeutics (NASDAQ:TGTX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
TG테라퓨틱스사 (TGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):